1. Home
  2. NIU vs MDWD Comparison

NIU vs MDWD Comparison

Compare NIU & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Niu Technologies

NIU

Niu Technologies

HOLD

Current Price

$1.89

Market Cap

147.5M

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$12.32

Market Cap

162.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIU
MDWD
Founded
2014
2000
Country
China
Israel
Employees
N/A
N/A
Industry
Auto Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.5M
162.2M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
NIU
MDWD
Price
$1.89
$12.32
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$2.55
★ $30.67
AVG Volume (30 Days)
★ 181.7K
60.8K
Earning Date
11-16-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.29
$39.60
Revenue Next Year
$22.76
$34.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.79
$11.84
52 Week High
$4.58
$19.70

Technical Indicators

Market Signals
Indicator
NIU
MDWD
Relative Strength Index (RSI) 42.35 38.38
Support Level $1.81 N/A
Resistance Level $2.04 $14.06
Average True Range (ATR) 0.05 0.44
MACD 0.00 -0.12
Stochastic Oscillator 48.15 16.36

Price Performance

Historical Comparison
NIU
MDWD

About NIU Niu Technologies

Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: